Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Celsion (CLN AMEX) was CELN -- Ignore unavailable to you. Want to Upgrade?

To: TEDennis who wrote (893)	9/13/2003 11:30:24 AM
From: Tech Master	Read Replies (1) \| Respond to of 966

I hate when that happens... our little frog is well on its way to becoming a prince.

To: TEDennis who wrote (893)	9/16/2003 9:43:04 AM
From: Tech Master	Read Replies (1) \| Respond to of 966

Press Release Source: Celsion Corporation Celsion Obtains Exclusive License for Heat-Activated Gene Therapy Technology from National Institutes of Health -- NIH -- Tuesday September 16, 9:15 am ET COLUMBIA, Md.--(BUSINESS WIRE)--Sept. 16, 2003--CELSION CORPORATION (AMEX:CLN - News) announced today that it has acquired exclusive worldwide commercialization rights to a package of proprietary gene therapy technologies developed by scientists at the National Institutes of Health The technology is covered by a pending NIH patent application, detailing the use of heat energy to activate and control gene therapy and the construction of various heat-sensitive "Gene Therapy Constructs." Under the license agreement, Celsion has the exclusive rights to develop heat-sensitive gene therapy products activated by microwave heat energy. Celsion believes that its proprietary microwave-focused heating technology, which targets tumors, is an ideal tool for activation and control of heat-sensitive gene therapies. The addition of the NIH technology package to Celsion's technology portfolio significantly strengthens the Company's position as a technology leader in the development of heat-activated gene therapy for targeted treatment of cancer and other localized diseases. Celsion currently owns exclusive worldwide rights to a heat-activated, anti-sense genetic biological modifier developed at Memorial Sloan-Kettering Cancer Center and has an option to acquire from Duke University a technology that uses heat to induce genetic anti-angiogenesis and to regulate immunogene therapy. Results of preclinical studies involving both of these technologies have been published in Cancer Research (Memorial Sloan-Kettering: Volume 63, 2003 and Duke: Volume 60, 2000). Celsion is working with scientists at both institutions to develop these technologies further. Access to the new NIH technology package will add strength and depth to the Company's intellectual property portfolio for current and future development. Dr. Augustine Y. Cheung, Chief Executive Officer and Chief Scientific Officer of Celsion, stated, "We are very excited to have acquired this technology from NIH. This proprietary technology significantly strengthens our intellectual property portfolio and enhances our leadership position in the area of heat-activated, gene-based cancer treatments. Work recently published by Dr. Gloria Li from Memorial Sloan-Kettering suggests that our heat-activated, anti-sense biological modifier may strongly sensitize tumor cells to radiation. When used in conjunction with radiation therapy and activated by focused heat, the modifier could improve the efficacy of, and greatly reduce the toxicity and side effects associated with, radiation therapy. Our microwave heating technology, together with the technology covered by the NIH patent, forms a platform from which many controllable tumor targeting genetic products could be derived." About Celsion: Celsion Corporation, based in Columbia, Maryland, is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused-heat energy delivered by patented microwave technology. In January 2003, Celsion entered into a strategic alliance with Boston Scientific Corporation (NYSE:BSX - News) in which Boston Scientific will initially distribute Celsion's BPH product worldwide. Boston Scientific currently owns approximately 7% of Celsion's outstanding stock. Celsion has research, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: www.celsion.com. Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. --------------------------------------------------------------------------------